Alexion hit by surprise inter partes review as Amgen challenges Soliris patents
Amgen is coming for Alexion — but not in the form of a rumored, and largely dispelled, takeover.
Rather, the US Patent Trials Appeal Board (PTAB) has agreed to conduct an inter partes review on Alexion’s Soliris. Amgen, which is pushing a biosimilar to the complement inhibitor, filed the IPR in an effort to overturn patents on the composition eculizumab (the active ingredient in Soliris), its formulation, and its use to treat certain diseases, including the key indication of paroxysmal nocturnal hemoglobinuria.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.